AMEDISYS INC (AMED) Stock Fundamental Analysis
USA - NASDAQ:AMED - US0234361089 - Common Stock
100.99 USD
+0.01 (+0.01%)
100.99 USD
0 (0%)
Taking everything into account, AMED scores 5 out of 10 in our fundamental rating. AMED was compared to 101 industry peers in the Health Care Providers & Services industry. While AMED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMED has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
AMED had positive earnings in the past year.
In the past year AMED had a positive cash flow from operations.
Of the past 5 years AMED 4 years were profitable.
In the past 5 years AMED always reported a positive cash flow from operatings.
1.2 Ratios
With a decent Return On Assets value of 3.87%, AMED is doing good in the industry, outperforming 72.12% of the companies in the same industry.
AMED has a Return On Equity of 6.95%. This is in the better half of the industry: AMED outperforms 66.35% of its industry peers.
Looking at the Return On Invested Capital, with a value of 10.34%, AMED belongs to the top of the industry, outperforming 81.73% of the companies in the same industry.
AMED had an Average Return On Invested Capital over the past 3 years of 9.73%. This is in line with the industry average of 9.19%.
The last Return On Invested Capital (10.34%) for AMED is above the 3 year average (9.73%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROIC | 10.34% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
1.3 Margins
AMED's Profit Margin of 3.56% is fine compared to the rest of the industry. AMED outperforms 68.27% of its industry peers.
AMED's Profit Margin has declined in the last couple of years.
AMED has a Operating Margin of 9.41%. This is in the better half of the industry: AMED outperforms 78.85% of its industry peers.
In the last couple of years the Operating Margin of AMED has remained more or less at the same level.
The Gross Margin of AMED (43.19%) is better than 71.15% of its industry peers.
AMED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% |
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AMED is still creating some value.
AMED has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AMED has more shares outstanding
AMED has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 4.10 indicates that AMED is not in any danger for bankruptcy at the moment.
AMED has a better Altman-Z score (4.10) than 75.00% of its industry peers.
The Debt to FCF ratio of AMED is 1.55, which is an excellent value as it means it would take AMED, only 1.55 years of fcf income to pay off all of its debts.
AMED's Debt to FCF ratio of 1.55 is amongst the best of the industry. AMED outperforms 85.58% of its industry peers.
AMED has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.26, AMED is doing good in the industry, outperforming 65.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Altman-Z | 4.1 |
ROIC/WACC1.2
WACC8.61%
2.3 Liquidity
AMED has a Current Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED has a Current ratio (1.36) which is in line with its industry peers.
AMED has a Quick Ratio of 1.36. This is a normal value and indicates that AMED is financially healthy and should not expect problems in meeting its short term obligations.
AMED has a Quick ratio of 1.36. This is comparable to the rest of the industry: AMED outperforms 50.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 |
3. Growth
3.1 Past
AMED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.24%, which is quite good.
Measured over the past years, AMED shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.46% on average per year.
Looking at the last year, AMED shows a small growth in Revenue. The Revenue has grown by 4.93% in the last year.
AMED shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.73% yearly.
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
3.2 Future
Based on estimates for the next years, AMED will show a small growth in Earnings Per Share. The EPS will grow by 6.47% on average per year.
The Revenue is expected to grow by 4.95% on average over the next years.
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.26 indicates a rather expensive valuation of AMED.
Based on the Price/Earnings ratio, AMED is valued a bit cheaper than the industry average as 67.31% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.41. AMED is valued slightly cheaper when compared to this.
AMED is valuated rather expensively with a Price/Forward Earnings ratio of 19.15.
AMED's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AMED is cheaper than 62.50% of the companies in the same industry.
AMED is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.87, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, AMED is valued a bit cheaper than 65.38% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMED is valued a bit cheaper than the industry average as 78.85% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.18 | ||
| EV/EBITDA | 11.63 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AMED has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.61
PEG (5Y)N/A
EPS Next 2Y10.6%
EPS Next 3Y6.47%
5. Dividend
5.1 Amount
No dividends for AMED!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
100.99
+0.01 (+0.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners92.54%
Inst Owner Change2.85%
Ins Owners1.88%
Ins Owner Change-34.96%
Market Cap3.32B
Analysts54.12
Price Target102.87 (1.86%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.78%
Min EPS beat(2)12.12%
Max EPS beat(2)13.43%
EPS beat(4)2
Avg EPS beat(4)-0.15%
Min EPS beat(4)-15.99%
Max EPS beat(4)13.43%
EPS beat(8)3
Avg EPS beat(8)-1.75%
EPS beat(12)6
Avg EPS beat(12)2.15%
EPS beat(16)9
Avg EPS beat(16)3.64%
Revenue beat(2)1
Avg Revenue beat(2)-1.09%
Min Revenue beat(2)-2.2%
Max Revenue beat(2)0.01%
Revenue beat(4)1
Avg Revenue beat(4)-1.56%
Min Revenue beat(4)-2.2%
Max Revenue beat(4)0.01%
Revenue beat(8)2
Avg Revenue beat(8)-1.41%
Revenue beat(12)2
Avg Revenue beat(12)-2.17%
Revenue beat(16)2
Avg Revenue beat(16)-2.65%
PT rev (1m)0%
PT rev (3m)0.02%
EPS NQ rev (1m)7.75%
EPS NQ rev (3m)3.52%
EPS NY rev (1m)0%
EPS NY rev (3m)0.36%
Revenue NQ rev (1m)0.63%
Revenue NQ rev (3m)-0.23%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.26 | ||
| Fwd PE | 19.15 | ||
| P/S | 1.38 | ||
| P/FCF | 14.18 | ||
| P/OCF | 13.87 | ||
| P/B | 2.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 11.63 |
EPS(TTM)4.75
EY4.7%
EPS(NY)5.27
Fwd EY5.22%
FCF(TTM)7.12
FCFY7.05%
OCF(TTM)7.28
OCFY7.21%
SpS73.04
BVpS37.47
TBVpS-1.84
PEG (NY)1.61
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.87% | ||
| ROE | 6.95% | ||
| ROCE | 13.09% | ||
| ROIC | 10.34% | ||
| ROICexc | 12.85% | ||
| ROICexgc | 184.87% | ||
| OM | 9.41% | ||
| PM (TTM) | 3.56% | ||
| GM | 43.19% | ||
| FCFM | 9.75% |
ROA(3y)2.52%
ROA(5y)6.1%
ROE(3y)4.72%
ROE(5y)11.86%
ROIC(3y)9.73%
ROIC(5y)11.44%
ROICexc(3y)10.87%
ROICexc(5y)12.42%
ROICexgc(3y)283.58%
ROICexgc(5y)337.19%
ROCE(3y)12.32%
ROCE(5y)14.48%
ROICexcg growth 3Y57.65%
ROICexcg growth 5Y52.31%
ROICexc growth 3Y-5.72%
ROICexc growth 5Y-4.31%
OM growth 3Y-10.17%
OM growth 5Y-0.51%
PM growth 3Y-42.02%
PM growth 5Y-22.26%
GM growth 3Y-1.85%
GM growth 5Y1.03%
F-Score6
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 1.55 | ||
| Debt/EBITDA | 1.13 | ||
| Cap/Depr | 8.5% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 8.42 | ||
| Cash Conversion | 83.2% | ||
| Profit Quality | 273.49% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.36 | ||
| Altman-Z | 4.1 |
F-Score6
WACC8.61%
ROIC/WACC1.2
Cap/Depr(3y)21.03%
Cap/Depr(5y)20.63%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.24%
EPS 3Y-10.14%
EPS 5Y-0.46%
EPS Q2Q%16.67%
EPS Next Y13.17%
EPS Next 2Y10.6%
EPS Next 3Y6.47%
EPS Next 5YN/A
Revenue 1Y (TTM)4.93%
Revenue growth 3Y1.98%
Revenue growth 5Y3.73%
Sales Q2Q%5.19%
Revenue Next Year4.17%
Revenue Next 2Y4.73%
Revenue Next 3Y4.95%
Revenue Next 5YN/A
EBIT growth 1Y8.08%
EBIT growth 3Y-8.39%
EBIT growth 5Y3.2%
EBIT Next Year19.91%
EBIT Next 3Y9.46%
EBIT Next 5YN/A
FCF growth 1Y132.55%
FCF growth 3Y5.56%
FCF growth 5Y2%
OCF growth 1Y110.02%
OCF growth 3Y5.48%
OCF growth 5Y1.88%